Patents Assigned to Selective Genetics, Inc.
-
Patent number: 7148202Abstract: Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.Type: GrantFiled: June 12, 2002Date of Patent: December 12, 2006Assignee: Selective Genetics, Inc.Inventors: David Larocca, Andrew Baird, Wendy Johnson
-
Publication number: 20040138155Abstract: Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous system injury. Methods of making and using the disclosed devices and DNA are also described. In various embodiments, the invention also discloses compositions and devices that may further include a targeting agent, such as a polypeptide that is reactive with an FGF receptor (e.g., bFGF), or another ligand that binds to cell surface receptors on neuronal cells, or a support cell. The invention also discloses methods of promoting neuronal survival and regeneration via transfection of an axon as it grows through a device or composition of the present invention, or via transfection of a repair cell.Type: ApplicationFiled: January 17, 2003Publication date: July 15, 2004Applicants: Selective Genetics, Inc., University of Birmingham, King's CollegeInventors: Andrew Baird, Ana Maria Gonzalez, Ann Logan, Martin Berry
-
Patent number: 6723512Abstract: A genetic package display system and methodology for probing protein-protein interactions that lead to cell transduction, selecting and/or identifying internalizing ligands, target cells and tissues which internalize known or putative ligands, and cell transduction facilitating peptides is provided. A ligand displaying genetic package that carries a selectable marker (e.g., reporter, selection, etc.) and presents a ligand on its surface is utilized to identify internalizing ligands, tranduction facilitating peptides, and/or a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package. Also provided are methods for evolving a ligand displaying package to facilitate gene delivery or delivery of any desired agent (e.g., pharmaceutical, polypeptide, peptide, etc.) into a cell and/or targeting cellular compartments such as the nucleus, endosome, chloroplast, mitochondria, etc.Type: GrantFiled: May 24, 2001Date of Patent: April 20, 2004Assignee: Selective Genetics Inc.Inventors: David Larocca, Paul Kassner, Andrew Baird
-
Publication number: 20040029280Abstract: The present invention relates to gene therapy. In particular, therapeutic agents, therapeutic gene products, and compositions are disclosed. Various systems and methods useful in targeting and delivering non-native nucleotide sequences to specific cells are disclosed, wherein virus-antibody-ligand conjugates are used to facilitate targeting and delivery.Type: ApplicationFiled: April 3, 2003Publication date: February 12, 2004Applicants: Selective Genetics, Inc., University of BirminghamInventors: Barbara A. Sosnowski, Andrew Baird, Glenn F. Pierce, David T. Curiel, Joanne T. Douglas, Buck E. Rogers
-
Publication number: 20030148263Abstract: A genetic package display system and methodology for probing protein-protein interactions that lead to cell transduction, selecting and/or identifying internalizing ligands, target cells and tissues which internalize known or putative ligands, and cell transduction facilitating peptides is provided. A ligand displaying genetic package that carries a selectable marker (e.g., reporter, selection, etc.) and presents a ligand on its surface is utilized to identify internalizing ligands, tranduction facilitating peptides, and/or a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package. Also provided are methods for evolving a ligand displaying package to facilitate gene delivery or delivery of any desired agent (e.g., pharmaceutical, polypeptide, peptide, etc.) into a cell and/or targeting cellular compartments such as the nucleus, endosome, chloroplast, mitochondria, etc.Type: ApplicationFiled: May 17, 2002Publication date: August 7, 2003Applicant: Selective Genetics, Inc.Inventors: David Larocca, Paul Kassner, Andrew Baird, Michael Alan Burg
-
Publication number: 20030148979Abstract: Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest.Type: ApplicationFiled: October 2, 2002Publication date: August 7, 2003Applicant: Selective Genetics, Inc.Inventors: Barbara A. Sosnowski, Glenn Pierce
-
Publication number: 20030143217Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: ApplicationFiled: July 2, 2002Publication date: July 31, 2003Applicant: Selective Genetics, Inc.Inventors: J. Andrew Baird, Lois Ann Chandler, Barbara A. Sosnowski
-
Patent number: 6589730Abstract: A method for identifying specific protein-protein (i.e., ligand/anti-ligand) interactions that internalize and are detected by transgene expression. A ligand displaying genetic package that carries a reporter or selectable marker and presents a ligand or putative ligand on its surface is utilized to screen cells displaying known or putative anti-ligands for the ability to successfully internalize the ligand displaying genetic package.Type: GrantFiled: November 17, 1998Date of Patent: July 8, 2003Assignee: Selective Genetics, Inc.Inventors: David Larocca, Andrew Baird, Paul Kassner
-
Publication number: 20030082143Abstract: Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.Type: ApplicationFiled: June 12, 2002Publication date: May 1, 2003Applicant: Selective Genetics, Inc.Inventors: David Larocca, Andrew Baird, Wendy Johnson
-
Patent number: 6551618Abstract: Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous system injury. Methods of making and using the disclosed devices and DNA are also described. In various embodiments, the invention also discloses compositions and devices that may further include a targeting agent, such as a polypeptide that is reactive with an FGF receptor (e.g., bFGF), or another ligand that binds to cell surface receptors on neuronal cells, or a support cell. The invention also discloses methods of promoting neuronal survival and regeneration via transfection of an axon as it grows through a device or composition of the present invention, or via transfection of a repair cell.Type: GrantFiled: October 23, 1998Date of Patent: April 22, 2003Assignees: University of Birmingham, King's College, Selective Genetics, Inc.Inventors: Andrew Baird, Ana Maria Gonzalez, Ann Logan, Martin Berry
-
Patent number: 6537813Abstract: The invention relates generally to methods and apparatuses that are adapted for the preparation of gene therapeutic compositions, as well as the compositions formed thereby. The invention also relates to methods adapted for making mixtures and condensate compositions. In the various embodiments, the present invention provides controlled and uniform mixing of gene therapy vectors and gene therapy vector vehicles for improved reproducibility, scaleability, stability, and pharmaceutical efficacy. Such compositions are suitable for use in mediation of disease.Type: GrantFiled: February 16, 1999Date of Patent: March 25, 2003Assignee: Selective Genetics, Inc.Inventors: Xian Chen, Mark J. D'Andrea
-
Patent number: 6503886Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: GrantFiled: November 24, 1999Date of Patent: January 7, 2003Assignee: Selective Genetics, Inc.Inventors: J. Andrew Baird, Lois Ann Chandler, Barbara A. Sosnowski
-
Methods for identification on internalizing ligands and identification of known and putative ligands
Patent number: 6472146Abstract: A method for identifying target cells and tissues which internalize known or putative ligands is provided. A ligand displaying genetic package that carries a reporter or selectable marker and presents a ligand on its surface is utilized to screen a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package.Type: GrantFiled: November 17, 1998Date of Patent: October 29, 2002Assignee: Selective Genetics, Inc.Inventors: David Larocca, Andrew Baird, Paul Kassner -
Patent number: 6451527Abstract: A genetic package display system is presented for selecting internalizing ligands for gene delivery. The genetic package carries a reporter, selectable marker, or a specifically detectable nucleic acid sequence and presents a ligand on its surface. More specifically, a library of potential ligands may be screened for the ability to successfully transduce target cells.Type: GrantFiled: February 26, 1999Date of Patent: September 17, 2002Assignee: Selective Genetics, Inc.Inventors: David Larocca, Andrew Baird, Paul Kassner
-
Patent number: 6448083Abstract: Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.Type: GrantFiled: February 26, 1999Date of Patent: September 10, 2002Assignee: Selective Genetics, Inc.Inventors: David Larocca, Andrew Baird, Wendy Johnson
-
Patent number: 6251599Abstract: Preparations of nucleic acid condensates and compositions containing such condensates are provided. The nucleic acid condensates are in the form of small particles that are stable when subjected to destabilizing conditions such as lyophilizing, freeze-thawing, and prolonged liquid storage. These compositions may be used to deliver nucleic acid to cells.Type: GrantFiled: November 6, 1998Date of Patent: June 26, 2001Assignee: Selective Genetics, Inc.Inventors: Xian Chen, Chenglie Ma, Mark J. D'Andrea
-
Patent number: 6054312Abstract: Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.Type: GrantFiled: August 29, 1997Date of Patent: April 25, 2000Assignee: Selective Genetics, Inc.Inventors: David Larocca, Andrew Baird, Wendy Johnson
-
Patent number: 6037329Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: GrantFiled: September 24, 1996Date of Patent: March 14, 2000Assignee: Selective Genetics, Inc.Inventors: J. Andrew Baird, Lois Ann Chandler, Barbara A. Sosnowski